Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Protocol to Evaluate the Efficacy and Safety of Extended Use of OncoVEX GM-CSF
2010-021070-11Phase 3Completed
- Sponsor
- BioVex Group, Inc.
- Start
- Aug 2010
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by BioVex Group, Inc. Primary endpoint: Safety of extended use of OncoVEX GM-CSF. Started Aug 2010; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-021070-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021070-11.